Cancer/ News FDA fast-tracks Merck’s cancer blockbuster-in-waiting Linda Banks 0 Comment Merck KGaA’s blockbuster candidate evofosfamide has been granted fast-track status from the US FDA for advanced pancreatic cancer. Share X FDA fast-tracks Merck’s cancer blockbuster-in-waiting https://pharmaphorum.com/news/fda-fast-tracks-mercks-cancer-blockbuster-in-waiting/
News What next for GSK as new chairman takes position? Linda Banks 0 Comment The appointment of a new chairman at GlaxoSmithKline (GSK) has led to questions about the future direction at Share X What next for GSK as new chairman takes position? https://pharmaphorum.com/news/what-next-for-gsk-as-new-chairman-takes-position/
News GSK renews commitment to HIV with cure centre Linda Banks 0 Comment GlaxoSmithKline (GSK) has set up a partnership with a US university that will focus on finding a cure Share X GSK renews commitment to HIV with cure centre https://pharmaphorum.com/news/gsk-renews-commitment-to-hiv-with-cure-centre/
News Tories to take control, but tough calls on health spending, unity and Europe ahead Andrew McConaghie 0 Comment The Conservative party has confounded expectations of a hung parliament in the UK, and are set to win Share X Tories to take control, but tough calls on health spending, unity and Europe ahead https://pharmaphorum.com/news/tories-take-control-but-tough-calls-on-health-spending-unity-and-europe-ahead/
News Investors cautious on Alexion’s $8.4bn Synageva bid Andrew McConaghie 0 Comment Alexion is confident its $8.4bn takeover of Synageva will give it another blockbuster product – but a slump in its Share X Investors cautious on Alexion’s $8.4bn Synageva bid https://pharmaphorum.com/news/investors-cautious-on-alexion-s-8-4bn-synageva-bid/
News Roche’s leukaemia drug granted breakthrough status Andrew McConaghie 0 Comment A new drug from Roche and AbbVie has been given ‘breakthrough’ status by the FDA for patients with a Share X Roche’s leukaemia drug granted breakthrough status https://pharmaphorum.com/news/roches-leukaemia-drug-granted-breakthrough-status/
News Lundbeck’s new leader Schultz faces tough task Andrew McConaghie 0 Comment Instead of easing into the chief executive role at a buoyant Novo Nordisk, Kåre Schultz has taken on Share X Lundbeck’s new leader Schultz faces tough task https://pharmaphorum.com/news/lundbecks-new-leader-schultz-faces-tough-task/
Cancer/ News Rising cancer drug costs add to patients’ financial burden Andrew McConaghie 0 Comment Global spending on cancer drugs exceeded $100 billion for the first time everlast year, creating growing concerns about Share X Rising cancer drug costs add to patients’ financial burden https://pharmaphorum.com/news/rising-cancer-drug-costs-add-to-patients-financial-burden/
News Novo Nordisk invests in haemophilia franchise Linda Banks 0 Comment Novo Nordisk has started work on a 1.5 billion kroner ($225 million) manufacturing facility in Denmark to support Share X Novo Nordisk invests in haemophilia franchise https://pharmaphorum.com/news/novo-nordisk-invests-in-haemophilia-franchise/
